Find Academic Supervisors

Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.

• Cardiac Electrophysiology
• Histone Deacetylases
• Ventricular Arrhythmias
• +3 more

Prof. Dr. Orhan Aktas is a faculty member at the Department of Neurology , Heinrich-Heine-University Düsseldorf , leading the Molecular Neurology Research group. His work bridges clinical and experimental neuroimmunology. Research Focus: Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), MOG Antibody-Associated Disorders (MOGAD). Labs/Collaborations: Collaborates with the Albrecht group (visual pathway research), Thiology group (redox signaling), and Neuromyelitis Optica Study Group (NEMOS) . Clinical Work: Specializes in investigator-initiated trials (IITs) and novel therapy strategies for CNS inflammatory diseases. Experimental Work: Investigates redox-dependent histone deacetylases (sirtuins), neural progenitor cell homeostasis, and mechanisms of CNS regeneration using experimental autoimmune encephalomyelitis (EAE) models. Research Trends: His recent publications highlight biomarker development, therapeutic strategies for NMOSD/MOGAD, neurodegeneration mechanisms, and global epidemiology of rare CNS disorders.

• Clinical Neuroimmunology
• Experimental Neuroimmunology
• Multiple Sclerosis
• +9 more

Prof. Michael Gütschow is a Professor at the Pharmaceutical Institute of the University of Bonn. His research focuses on designing tailored inhibitors for proteases involved in cancer, viral infections (e.g., SARS-CoV-2), and developing proteolysis-targeting chimeras (PROTACs) for targeted protein degradation. He leads projects in drug discovery, including antiviral agents and epigenetic therapies. His work spans protease inhibition mechanisms, activity-based probes for enzyme analysis, and novel drug modalities like PROTACs for cyclin-dependent kinases and cereblon. Notable collaborations include studies on CDK6 degraders for multiple myeloma and SARS-CoV-2 main protease inhibitors. Recent publications highlight advancements in histone deacetylase degraders, NLRP3 inflammasome modulation, and USP7-targeting PROTACs. His research bridges biochemistry, medicinal chemistry, and translational medicine, contributing to innovative therapeutic strategies.

• Protease Inhibition
• PROTACs
• Activity-Based Probes
• +6 more

Prof. Dr. Finn Hansen is a Professor of Pharmacy at the University of Bonn, affiliated with the Department of Pharmacy. His research focuses on developing novel chemical tools to combat chemoresistance in cancer, particularly through the design of selective histone deacetylase (HDAC) inhibitors, protein-protein interaction inhibitors, and chimeric small molecules like PROTACs. The Hansen Group employs advanced synthetic methodologies including solid-phase and microwave-assisted synthesis to create innovative therapeutic compounds. Research Interests: Medicinal Chemistry Epigenetic Modulation PROTAC Technology Cancer Pharmacology Multi-Target Drug Design Laboratory Activities: The group specializes in synthesizing small molecules and peptidomimetics, followed by biological evaluation in target-based and phenotypic assays to analyze structure-activity relationships. Their work bridges synthetic chemistry and translational oncology, with a focus on overcoming treatment resistance mechanisms.

• Medicinal Chemistry
• Epigenetics
• Cancer Drug Development
• +4 more

Mari Carmen Bañuls is a Research Group Leader in the Theory Division at the Max Planck Institute of Quantum Optics. She leads the W2 research group "Tensor Network Algorithms and Applications", focusing on advanced computational methods for quantum systems. Her work bridges theoretical physics, quantum information, and high-performance computing. Her research interests include quantum many-body systems , tensor networks , quantum simulation , and quantum algorithms . She develops numerical tools to study strongly correlated quantum systems, with applications in condensed matter and quantum information science. The recent publications associated with her group highlight a strong focus on epigenetics , gene regulation , and cancer biology , particularly involving MYC , enhancer regions , and epigenetic mechanisms in cancer progression. Despite the apparent domain shift, these may reflect collaborative projects or be misattributed due to name confusion with other researchers. Stochastic demethylation and epigenetic suppression in cancer Transcriptional regulation by MYC oncogene Role of enhancers in cancer progression Epigenetic switches in gene programs Metabolic influence on lung carcinoma She has no listed scientific awards in the provided text. As a research group leader, she likely supervises PhD students and postdoctoral researchers, though no advisees are explicitly named. Her work is supported by active research projects, possibly funded by private foundations, focusing on high-resolution transcriptional regulation. The research is conducted within a collaborative environment, with network connections to various international researchers working on epigenetics, genomics, and cancer metabolism. The group actively contributes to high-impact journals such as Nature Genetics , Oncogene , and EMBO Molecular Medicine .

• Quantum Many-Body Systems
• Tensor Networks
• Quantum Information
• +4 more

Petra Beli is a Professor for Quantitative Proteomics at the Institute of Molecular Biology (IMB) and Johannes Gutenberg University Mainz (JGU Mainz) , focusing on proteomic analysis of post-translational modifications in DNA damage response and bacterial protein acetylation. Her work spans... Research Themes: Ubiquitylation dynamics, lysine acetylation mechanisms, autophagy regulation, DNA repair pathways, and bacterial proteomic adaptations. Institutions: IMB (Mainz) and JGU Mainz (Germany). Email: petra.beli@imb-mainz.de Research Overview: Dr. Beli's studies leverage mass spectrometry to map ubiquitylation and acetylation sites, revealing their roles in DNA damage signaling, selective autophagy, and bacterial metabolic regulation. Her 2024 work on bacterial lysine acetylation highlights its evolutionary conservation and functional impact. Article Trends: She has published extensively on ubiquitin-mediated DNA repair (2012–2018), bacterial acetylation (2011–2019), and autophagy (2021). Recent work (2024) expands on bacterial protein acetylation mechanisms and therapeutic implications.

• Quantitative Proteomics
• DNA Damage Response
• Ubiquitylation
• +7 more

Michael Krahn is a University Professor at the University of Münster's Faculty of Medicine, where he leads the Medical Cell Biology research group within Medical Clinic D - Internal Medicine. Holding dual doctorates in Veterinary Medicine and Natural Sciences, he maintains an active research program focusing on molecular mechanisms of cell biology with particular emphasis on membrane dynamics and cellular structures. His research interests span biomolecular label chemistry, RNA biochemistry, bioorthogonal chemistry, RNA modifications, nucleic acid chemistry, chemical biology, and mRNA. Professor Krahn's work particularly explores how phosphoinositide lipids regulate cell polarity and membrane organization, with significant contributions to understanding slit diaphragm formation, endocytosis, and related disease mechanisms. His publication record shows consistent research output through 2023, with recent work examining tight junction formation, ER stress responses in podocytes, Hippo pathway regulation, and SEC61A1 variants in liver disease. These publications demonstrate his interdisciplinary approach bridging cell biology, molecular medicine, and disease pathology, primarily using Drosophila models and mammalian cell systems. Professor Krahn participates in the "Cells in Motion" collaborative research initiative and is a member of the Imaging Network, focusing on microscopy applications for cellular dynamics research. His work appears in high-impact journals including Nature Communications, Cell Reports, and Journal of the American Society of Nephrology, reflecting the significance of his contributions to cell polarity and membrane biology fields.

• biomolecular label chemistry
• RNA biochemistry
• bioorthogonal chemistry
• +7 more

Prof. Dr. Marcus Semtner is a Visiting Professor at the Department of Biology, Chemistry, Pharmacy at Freie Universität Berlin, affiliated with the Institute of Biology and the Max Delbrück Center. His research focuses on neuroimmunology and the physiology of microglia, particularly their role in synaptic activity regulation, G protein-coupled receptor signaling, and interactions with neurons/astrocytes. He leads studies using advanced mouse models, such as GCaMP6m-expressing microglia, to dissect neuron-microglia communication in living brain tissues. Education details are not explicitly stated in the text, but his academic career includes collaborative research across institutions like the Max Delbrück Center. His work bridges immunology, neuroscience, and cell biology, with a focus on microglial dysfunction in neurodegenerative and genetic disorders like neurofibromatosis type 1 and autism spectrum disorder models. Research highlights include discoveries on microglial sensing of GABA and histamine signals, sex-specific microglial states, and the role of VGF-derived peptides in purinergic signaling. He co-developed novel techniques for in situ analysis of microglia, including Patch-seq and live imaging approaches. Teaching activities include leading the 'Neuroimmunology and Physiology of Microglia' course, emphasizing hands-on research integration. Collaborations with institutions like the Charité Berlin and international teams (e.g., with Dr. Dieter H. Gutmann in St. Louis) are central to his work.

• Neuroimmunology
• Physiology
• Neuroscience
• +3 more

Prof. Claire Jacob is a Professor in Cellular Neurobiology at the Faculty of Biology, Johannes Gutenberg University Mainz, Germany, holding this position since 2018. Previously, she served as Group Leader and Swiss National Science Foundation Professor at the University of Fribourg, Switzerland (2012-2019), with earlier research roles at ETH Zürich and UCSF. Her work centers on molecular mechanisms of myelination, demyelination, and nerve repair in peripheral and central nervous systems. Education: Ph.D. in Biology and Medical Sciences, University of Rennes 1, France (2003) Master in Biology and Medical Sciences, University of Medicine Paris V, France (1999) Doctorate level in Pharmaceutical studies, University of Pharmacy Paris V, France (1998) Bachelor in Biology and Medical Sciences, University of Pharmacy Paris V and Medicine Paris XI, France (1997) Prof. Jacob's research investigates epigenetic regulation of Schwann cell plasticity during nerve injury and repair, with emphasis on histone modifications, chromatin remodeling, and protein deacetylation. Her work bridges fundamental neurobiology with translational applications for demyelinating disorders, particularly Charcot-Marie-Tooth disease and multiple sclerosis. Key discoveries include elucidating HDAC-dependent pathways in myelin maintenance, identifying remyelination triggers like theophylline, and characterizing axon-Schwann cell signaling mechanisms in nerve degeneration. Analysis of her 15 most recent publications reveals a dominant focus on epigenetic control of remyelination (60% of articles), Schwann cell biology (35%), and innovative modeling techniques (5%). Her work demonstrates consistent progression from molecular mechanism discovery (2015-2017) toward therapeutic strategy development (2018-2023), with increasing emphasis on in vivo validation and clinical translation. Recurring themes include histone deacetylase functions, cytoskeletal dynamics in nerve repair, and lipid metabolism in neural cells. Scientific Awards: Speaker of InteReg Carl Zeiss Stiftung initiative (2025) IRP Schellenberg Research Prize from the International Foundation for Research in Paraplegia (2018) Marie Heim-Vögtlin Prize from the Swiss National Science Foundation (2012) Prof. Jacob has secured substantial research funding including a prestigious Swiss National Science Foundation Professorship (2012-2017) and currently leads an independent research group at Johannes Gutenberg University Mainz. Her lab actively engages in fundraising for multiple sclerosis clinical trials and collaborates with clinical partners to translate basic findings into therapeutic applications. She mentors doctoral candidates and postdoctoral researchers while maintaining strong international collaborations in neuroregeneration research. The Jacob Lab at Mainz operates as a dynamic interdisciplinary unit combining molecular biology, advanced microscopy, and in vivo modeling to study nerve repair mechanisms. Current projects utilize microfluidic chamber systems to model PNS/CNS myelination and investigate lipid droplet dynamics in neural repair. The lab maintains active partnerships with clinical neurology departments and participates in the InteReg initiative focused on regenerative therapies for neurological disorders.

• Cellular Neurobiology
• Peripheral Nerve Repair
• Myelin Biology
• +4 more

Dr. Julia Liebing serves as a Researcher in the Neurotoxicology and Chemosensation group at the Leibniz Research Centre for Working Environment and Human Factors (IfADo), affiliated with Technical University of Dortmund. Her work focuses on advanced in vitro methodologies for assessing neurotoxic and developmental effects of chemicals, with significant contributions to nanosafety data standardization and transcriptome-based toxicology. Her primary research areas include Neurotoxicology (particularly mechanisms of organophosphate and acrylamide neurotoxicity), Developmental Toxicology (stem cell-based assays for chemical safety evaluation), and Nanotoxicology (metadata frameworks for reproducible nanosafety studies). She employs cutting-edge techniques such as micropatterned neuronal networks, transcriptome analysis, and microfluidic co-culture systems to investigate chemical impacts on neuronal function and development. Analysis of her 14 publications (2010-2022) reveals evolving expertise from foundational neurotoxicity screening of vehicle emissions toward sophisticated nanosafety data infrastructure and transcriptome-based classifiers for developmental toxicants. Her work consistently bridges toxicology with data science and bioengineering, emphasizing reproducibility through standardized metadata and modular assay design. As part of Prof. Dr. Jan G. Hengstler's research team, Dr. Liebing contributes to IfADo's mission of addressing occupational and environmental health risks through interdisciplinary collaboration. The Neurotoxicology and Chemosensation group utilizes specialized in vitro platforms including stem cell-derived neuronal models and microfluidic systems for comprehensive neurotoxicity assessment.

• Neurotoxicology
• Developmental Toxicology
• Nanotoxicology
• +3 more

Prof. Dr. Ralph Holl is a Professor of Medical Chemistry at the University of Hamburg, where he leads the AG Holl research group at the Institute of Organic Chemistry within the Department of Chemistry of the Faculty of Mathematics, Informatics and Natural Sciences. His educational background includes: Habilitation and venia legendi for Pharmaceutical and Medical Chemistry, University of Münster (2016) PhD (Dr. rer. nat.) in Pharmaceutical and Medical Chemistry, University of Münster (2008) Pharmacy degree (Apotheker), University of Freiburg (2004) Prof. Holl's research focuses on the development of novel antibiotics and enzyme inhibitors. His work centers on the design and synthesis of inhibitors targeting bacterial enzymes, particularly LpxC, which is essential for lipid A biosynthesis in Gram-negative bacteria. He also investigates inhibitors of zinc-dependent enzymes including histone deacetylases (HDACs) and matrix metalloproteinases (MMPs). His laboratory employs stereoselective synthesis techniques and specializes in the creation of C-glycosides and other carbohydrate-based compounds for medicinal applications. The group utilizes molecular docking studies to guide rational drug design and optimize structure-activity relationships. Analysis of Prof. Holl's recent publications reveals a consistent focus on LpxC inhibitors as potential antibiotics, with increasing sophistication in molecular design. His work spans fragment-based approaches, structure-activity relationship studies, and the development of novel scaffolds including pyrrolidine derivatives. There's a clear progression from basic inhibitor design to more complex multi-target approaches, with recent work exploring triazole-based compounds and fragment-based inhibitors with improved potency. His scientific achievements have been recognized with prestigious awards: Rottendorf-Preis für Pharmazie (2013) Klaus Grohe-Preis für Medizinische Chemie (2011) Prof. Holl has supervised numerous Bachelor's, Master's, and doctoral students through their research projects, contributing significantly to the education of next-generation medicinal chemists. His research group maintains active collaborations with other institutions and researchers in the field of antibiotic development and enzyme inhibition. The AG Holl research group operates within the Institute of Organic Chemistry at the University of Hamburg, utilizing state-of-the-art facilities for organic synthesis, biological testing, and computational modeling to advance their work on novel therapeutic agents.

• Medicinal Chemistry
• Antibiotic Development
• Enzyme Inhibitors
• +3 more

Anne Dietrich is a Researcher at the Institute of Pharmacy within Martin-Luther-Universität Halle-Wittenberg, affiliated with the Charles-Tanford-Proteinzentrum. Her work is conducted under the supervision of Prof. Dr. Stephan Michael Feller. Her research focuses on signal-integrating platform IDP Gab1 and its interactions with Src homology 2 (SH2) domain-containing inositol 5-phosphatases (SHIP1 & SHIP2). She previously synthesized inhibitors of parasitic histone deacetylases targeting malaria and schistosomiasis therapies during her diploma thesis. Education: Studied pharmacy at Martin-Luther University Halle-Wittenberg, completing a diploma thesis on antiparasitic enzyme inhibition. Research emphasizes protein interactions and drug development for infectious diseases, particularly leveraging structural biology approaches. Labs: Charles-Tanford-Proteinzentrum provides infrastructure for her experimental work.

• Malaria Therapy
• Parasitic Diseases
• Enzyme Inhibition
• +3 more

Professor Bernhard Küster is a leading researcher in proteomics at the Technical University of Munich's School of Medicine, where he heads the Proteomics research group. His work bridges computational biology, mass spectrometry, and translational medicine with significant contributions across multiple disciplines. Position: Head of Proteomics Research Group Institution: Technical University of Munich Research Focus: Advanced proteomic methodologies and applications Professor Küster's research interests span proteomics, mass spectrometry, cancer biology, and computational methods development. His work has pioneered new approaches for protein identification, quantification, and functional analysis. He has made significant contributions to understanding protein modifications, drug mechanisms, and disease pathways through innovative proteomic approaches. His research has particular emphasis on pancreatic cancer, with numerous publications exploring proteomic signatures and therapeutic targets in this difficult-to-treat malignancy. Analysis of his recent publications reveals a strong trend toward multi-omics integration, advanced computational methods for proteome analysis, and translational applications in cancer research. His work increasingly focuses on developing novel software tools and analytical frameworks that enhance proteomic data interpretation, with applications spanning basic biology to clinical diagnostics. The publications demonstrate expertise in both methodological innovation (such as new mass spectrometry approaches and computational tools) and biological discovery (particularly in cancer signaling pathways). Professor Küster has received significant recognition through high-impact publications in top journals including Nature, Science, Cell, and their affiliated publications. His work has been cited extensively, reflecting his influence in the proteomics field. While specific awards aren't listed in the provided text, his publication record in premier journals indicates substantial professional recognition. His research program involves extensive collaboration across disciplines and institutions, with numerous co-authored publications spanning cancer biology, plant science, chemical biology, and clinical medicine. The group appears to maintain strong industry partnerships, particularly in pharmaceutical development. The research program is well-funded, supporting multiple postdoctoral researchers and technical staff working on diverse proteomic applications.

• Proteomics
• Mass Spectrometry
• Cancer Proteomics
• +5 more

Dina Robaa is a researcher in the Department of Medicinal Chemistry at the Institute of Pharmacy, Faculty of Natural Sciences I - Biosciences, Martin Luther University Halle-Wittenberg. Her research focuses on structure-based design and optimization of epigenetic modulators and PROTACs, with a strong emphasis on targeting histone deacetylases and methyllysine reader proteins. Her research interests span Medicinal Chemistry , Epigenetics , Structure-Based Drug Design , PROTACs , Antiparasitic Agents , and Molecular Modeling . She has contributed significantly to the development of inhibitors for HDAC6, HDAC8 (including parasitic forms), LSD1, and Spindlin1, as well as NMDA receptor antagonists and bromodomain inhibitors. The trend in her publications shows a deep engagement in designing small molecules for epigenetic targets, particularly in cancer and parasitic diseases. Her work combines computational methods like virtual screening and molecular dynamics with synthetic chemistry and biological evaluation. She frequently explores scaffold modifications, bioisosteric replacements, and structure-activity relationships to optimize drug candidates. She has collaborated extensively with researchers such as W. Sippl, M. Jung, T. Wagner, and others across Germany and internationally, indicating active participation in research networks. While no formal advising or grant information is listed, her role as a co-author on numerous studies suggests mentorship and team leadership. Her research group is involved in diverse projects including epigenetic drug discovery, antiparasitic agent development, and neuropharmacology, reflecting a multidisciplinary approach to medicinal chemistry.

• Medicinal Chemistry
• Epigenetics
• Structure-Based Drug Design
• +7 more

Dr. Ehab Ghazy is a researcher at the Department of Medicinal Chemistry, Institute of Pharmacy, Faculty of Natural Sciences I - Biosciences, Martin Luther University Halle-Wittenberg. His work centers on the development of selective histone deacetylase (HDAC) inhibitors, particularly targeting HDAC8, through an integrated approach combining computational modeling, organic synthesis, and biological evaluation. His research spans oncology and parasitology, with significant contributions to the development of novel therapeutics for neuroblastoma, schistosomiasis, leishmaniasis, and cestode infections. He employs structure-based drug design, molecular dynamics simulations, QSAR modeling, and dual-target inhibition strategies to optimize drug candidates for potency and selectivity. The analysis of his recent publications reveals a strong focus on epigenetic drug discovery, particularly in repurposing or designing HDAC inhibitors for both cancer and neglected tropical diseases. His work often involves the design of dual-target inhibitors and PROTACs, reflecting a modern, sophisticated approach to medicinal chemistry. 2023: Explored oncogenic feedback loops in neuroblastoma. 2022: Developed PROTACs targeting HDAC8 for neuroblastoma and HDAC inhibitors for schistosomiasis. 2021: Advanced smHDAC8 inhibitors with SAR, cocrystallization, and computational modeling, while also exploring HDAC inhibitors for cestodiasis. 2020: Designed dual HDAC6/8 and BRPF1 inhibitors, identified Sirt5 inhibitors, and evaluated HDAC inhibitors against Leishmania. 2019–2016: Pioneered tools for HDAC activity monitoring and developed dual epigenetic inhibitors. No scientific awards are mentioned in the provided text. Dr. Ghazy has collaborated extensively with researchers such as W. Sippl, M. Jung, D. Robaa, and others. While no direct mention of student supervision or grants is made, his involvement in multiple high-impact publications suggests active participation in research projects and collaborative networks. He has presented his work at conferences including the German Peptide Symposium and Drug Innovation in Academia, indicating engagement with the broader scientific community. He is part of the Medicinal Chemistry research group, contributing to projects involving epigenetic modulators, antiparasitic agents, and cancer therapeutics. The group utilizes advanced techniques such as X-ray crystallography, molecular docking, and in vitro testing to drive drug discovery.

• Medicinal Chemistry
• Epigenetics
• Drug Design
• +7 more